HLA-DQ2/DQ8

Celiac disease (celiac enteropathy) is called immune-mediated systemic disease resulting from a genetic predisposition to persons. Almost all patients with celiac disease, a positive genetic risk factor HLA-DQ2 or HLA-DQ8. For this reason, a genetic test is important for both the approval and rejection of the diagnosis. Recommended when questionable serological or biopsy results (particularly in children under two years of age), where the diagnosis remains unclear after eliminating gluten from the diet products containing differentiation with other gastrointestinal diseases and others.

Test principle

The EUROArray is a test system for in vitro molecular genetic determination of disease-associated HLADQA1 and HLA-DQB1 alleles in human genomic DNA. In the first step of the analysis, in two parallel reactions, several sections of the HLA-DQA1 and HLA-DQB1 genes are amplified from patient genomic DNA using the polymerase chain reaction (PCR). For each reaction, a fragment of the N-acetyltransferase 2 (NAT2) gene is also amplified as a positive control. Amplification of the HLA-DQA1 and HLA-DQB1 gene sections only occurs if the sample contains one or more of the alleles being investigated. All PCR products are labelled with a fluorescence dye as they are produced. In the second reaction step, the products are analyzed using the microarray, which contains immobilized probes that are complementary to the amplified DNA.The specific binding (hybridization) of the fluorescing PCR products to the corresponding microarray spots is detected using a special microarray scanner (EUROIMMUN). Fluorescence signals at the HLA-DQA1 or HLA-DQB1 specific spots indicate the presence of the corresponding HLA-DQA1 or HLA-DQB1 allele in the DNA sample of the patient, and therefore also the presence of DQ2 and/or DQ8 where applicable. All spot signals are evaluated automatically using the EUROArrayScan program.

More information: www.euroimmun.com